Identification of human cytochrome P450 enzymes involved in the major metabolic pathway of fluvoxamine

References

• Aasmore L, Winberg JO, Aarbakke J. The role of liver alcohol dehydrogenase isoenzymes in the oxidation of glycolethers in male and female rats. Toxicology and Applied Pharmacology 1998; 150: 86–90
   Google Scholar
• Benfield P, Ward A. Fluvoxamine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986; 32: 313–334
   PubMed Web of Science ®Google Scholar
• Carrillo JA, Dahl ML, Svensson JO, Alm C, Rodriguez I, Bertilsson L. Disposition of fluvoxamine in human is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clinical Pharmacology and Therapeutics 1996; 60: 183–190
   PubMed Web of Science ®Google Scholar
• Christensen M, Tybring G, Mihara K, Yasui-Furukori N, Carrillo JA, Ramos SI, Andersson K, Dahl ML, Bertilsson L. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clinical Pharmacology and Therapeutics 2002; 71: 141–152
   PubMed Web of Science ®Google Scholar
• Donaldsson KM, Wright DM, Mathlener IS, Harry JD. The effect of fluvoxamine at steady state on the pharmacokinetics of theophylline after a single dose in healthy male volunteers. British Journal of Clinical Pharmacology 1994; 37: 492–496
   Google Scholar
• Droll K, Bruce-Mensah K, Otton SV, Gaedigk A, Sellers EM, Tyndale RF. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Pharmacogenetics 1998; 8: 325–333
   PubMedGoogle Scholar
• Hartter S, Grozinger M, Weigmann H, Roschke J, Hiemke C. Increased bioavailability of oral metatonin after fluvoxamine coadministration. Clinical Pharmacology and Therapeutics 2000; 67: 1–6
   PubMed Web of Science ®Google Scholar
• Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brosen K. Dose-dependent inhibition of CYP1A2, CYP2C9 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. European Journal of Clinical Pharmacology 1996a; 51: 73–78
   PubMed Web of Science ®Google Scholar
• Jeppesen U, Loft S, Poulsen HE, Brosen K. A fluvoxamine-caffeine interaction study. Pharmacogenetics 1996b; 6: 213–222
   PubMedGoogle Scholar
• Miura M, Ohkubo T. Simultaneous determination of fluvoxamine and its metabolites in human liver microsomes by high-performance liquid chromatography with solid-phase extraction. Analytical Letters 2006; 39: 2405–2415
   Web of Science ®Google Scholar
• Mori M, Kawajiri T, Sayama M, Miyahara T, Kozuka H. Metabolism of 2,4-dinitrotoluene and 2,6-dinitrotoluene, and their dinitrobenzyl alcohols and dinitrobenzaldehydes by Wistar and Sprague–Dawley rat liver microsomal and cytosol fractions. Chemical and Pharmaceutical Bulletin 1989; 37: 1904–1908
   Google Scholar
• Nakamura K, Ariyoshi N, Yokoi T, Ohgiya S, Chida M, Nagashima K, Inoue K, Kodama T, Shimada N, Kamataki T. CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability. Biochemical and Biophysical Research Communications 2002; 293: 969–973
   PubMed Web of Science ®Google Scholar
• Ohkubo T, Shimoyama R, Otani K, Yoshida K, Higuchi H, Shimizu T. High-performance liquid chromatographic determination of fluvoxamine and fluvoxamino acid in human plasma. Analytical Science 2003; 19: 859–864
   PubMed Web of Science ®Google Scholar
• Perucca E, Gatti G, Spina E. Clinical pharmacokinetics of fluvoxamine. Clinical Pharmacokinetics 1994; 27: 175–190
   PubMed Web of Science ®Google Scholar
• Ruijten HM, Bree HD, Borst AJM, Lange ND, Scherpenisse PM, Vincent WR, Post LC. Fluvoxamine: Metabolic fate in animals. Drug Metabolism and Disposition 1984; 12: 82–92
   PubMedGoogle Scholar
• Sperber AD. Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. Drug Safety 1991; 6: 460–462
   PubMed Web of Science ®Google Scholar
• Spigset O, Axelsson S, Norstrom A, Hagg S, Dahlqvist R. The major fluvoxamine metabolite in urine is formed by CYP2D6. European Journal of Clinical Pharmacology 2001; 57: 653–658
   PubMed Web of Science ®Google Scholar
• Spigset O, Carleborg L, Hedenmalm K, Dahlqvist R. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clinical Pharmacology and Therapeutics 1995; 58: 399–403
   PubMed Web of Science ®Google Scholar
• Spigset O, Granberg K, Hagg S, Norstrom A, Dahlqvist R. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. European Journal of Clinical Pharmacology 1997; 52: 129–133
   PubMed Web of Science ®Google Scholar
• Spigset O, Hagg S, Soderstrom E, Dahlqvist R. Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance. European Journal of Clinical Pharmacology 1999; 54: 943–946
   Google Scholar
• Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Therapeutic Drug Monitoring 1993; 15: 243–246
   PubMed Web of Science ®Google Scholar
• Sproule BA, Naranjo CA, Bremner KE, Hassan PC. Selective serotonin reuptake inhibitors and CNS drug interactions. Clinical Pharmacokinetics 1997; 33: 454–471
   PubMed Web of Science ®Google Scholar
• Wilde MI, Plosker GL, Benfield P. Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness. Drugs 1993; 46: 895–924
   PubMed Web of Science ®Google Scholar
• Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. A pharmacokinetic analysis program (MULTI) for microcomputer. Journal of Pharmacobiodynamics 1981; 4: 879–885
   PubMedGoogle Scholar
• Yu A, Kneller BM, Rettie AE, Haining RL. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. Journal of Pharmacology and Experimental Therapeutics 2002; 303: 1291–1300
   PubMed Web of Science ®Google Scholar
• Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedeberg's Archives of Pharmacology 2004; 369: 23–37
   PubMed Web of Science ®Google Scholar